Tag: Bayer

rivaroxaban

ESC 2017: Rivaroxaban significantly lowers risk of stroke, cardiovascular death, and...

The COMPASS study, which was presented at the European Society of Cardiology (ESC) congress (26–30 August, Barcelona, Spain), has shown that rivaroxaban (Xarelto, Bayer)...